PMID- 34967772
OWN - NLM
STAT- MEDLINE
DCOM- 20221122
LR  - 20221122
IS  - 2162-5220 (Electronic)
IS  - 1710-3568 (Linking)
VI  - 33
IP  - 6S
DP  - 2022 Nov-Dec 01
TI  - Impact of Extracorporeal Photopheresis on Blood Parameters of Atopic Dermatitis 
      Patients.
PG  - S37-S42
LID - 10.1097/DER.0000000000000835 [doi]
AB  - BACKGROUND: Extracorporeal photopheresis (ECP) is a safe treatment modality with 
      immunomodulatory effects. The latter may also explain efficacy of ECP in patients 
      with atopic dermatitis (AD). OBJECTIVE: We aimed to assess various blood 
      parameters of AD patients who underwent ECP over a maximum 1-year treatment 
      period. METHODS: We performed a retrospective single-center chart review 
      (clinical data, laboratory data) of adult patients with AD who had received for 
      at least 3 ECP cycles, in part combined with other treatment modalities. RESULTS: 
      We studied 60 patients with AD (85% extrinsic type, 15% intrinsic type) who had 
      median number of 14 (4-23) ECP cycles within a maximum 1-year treatment. When 
      compared with baseline, leukocytes and lymphocytes remained significantly 
      decreased after 3-, 6-, 9-, and 12-month ECP ( P = 0.014 and P = 0.0012, 
      respectively). A significant decline of eosinophils, as well as eosinophilic 
      cationic protein levels, was observed after 3-, 6-, 9-, and 12-month ECPs ( P = 
      0.011 and P = 0.0017, respectively). Total serum immunoglobulin E (IgE), as well 
      as lactate dehydrogenase, were significantly decreased at 3-, 6-, 9-, and 
      12-month evaluation compared with baseline ( P < 0.00001 and P = 0.00007, 
      respectively). Patients with slight or marked improvement of AD after their ECP 
      treatment period had significantly higher median baseline serum IgE levels than 
      patients who did not respond to ECP ( P = 0.0023). CONCLUSIONS: Several 
      laboratory parameters, including eosinophils, eosinophilic cationic protein, 
      total serum IgE, and lactate dehydrogenase, which declined under ECP, are 
      well-known disease biomarkers for AD patients. With normalization of the 
      abovementioned laboratory parameters, a clinical response to ECP treatment was 
      observed in almost two thirds of patients, confirming that ECP may be an 
      effective combination treatment modality for AD.
CI  - Copyright (c) 2022 American Contact Dermatitis Society. All Rights Reserved.
FAU - Gambichler, Thilo
AU  - Gambichler T
AD  - From the Department of Dermatology, Ruhr-University Bochum, Germany.
FAU - Steinbrecht, Kristina
AU  - Steinbrecht K
FAU - Chatzipantazi, Maria
AU  - Chatzipantazi M
FAU - Scheel, Christina H
AU  - Scheel CH
FAU - Stranzenbach, Rene
AU  - Stranzenbach R
FAU - Schmitz, Lutz
AU  - Schmitz L
FAU - Susok, Laura
AU  - Susok L
LA  - eng
PT  - Journal Article
DEP - 20220121
PL  - United States
TA  - Dermatitis
JT  - Dermatitis : contact, atopic, occupational, drug
JID - 101207335
RN  - EC 3.1.27.- (Eosinophil Cationic Protein)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - EC 1.1.- (Lactate Dehydrogenases)
SB  - IM
MH  - Humans
MH  - Adult
MH  - *Dermatitis, Atopic/drug therapy
MH  - *Photopheresis
MH  - Retrospective Studies
MH  - Eosinophil Cationic Protein
MH  - Immunoglobulin E
MH  - Lactate Dehydrogenases
COIS- The authors have no funding or conflicts of interest to declare.
EDAT- 2021/12/31 06:00
MHDA- 2022/11/23 06:00
CRDT- 2021/12/30 12:44
PHST- 2021/12/31 06:00 [pubmed]
PHST- 2022/11/23 06:00 [medline]
PHST- 2021/12/30 12:44 [entrez]
AID - 01206501-900000000-99413 [pii]
AID - 10.1097/DER.0000000000000835 [doi]
PST - ppublish
SO  - Dermatitis. 2022 Nov-Dec 01;33(6S):S37-S42. doi: 10.1097/DER.0000000000000835. 
      Epub 2022 Jan 21.